Literature DB >> 2133431

The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem.

B M Tune1, C Y Hsu.   

Abstract

The nephrotoxic beta-lactam antibiotics cephaloridine, cephaloglycin, and imipenem produce irreversible injury to renal mitochondrial anionic substrate uptake and respiration after 1 to 2 h of in vivo exposure. Toxicity during in vitro exposure is nearly identical but is immediate in onset and is reversed by the mitochondria being washed or the substrate concentrations being increased. A model of injury that accounts for these findings proposes that the beta-lactams fit carriers for mitochondrial substrate uptake, causing inhibition that is initially reversible and becomes irreversible as the antibiotics acylate the transporters. These studies were designed to create an environment of prolonged in vitro exposure, first, to determine whether toxicity becomes irreversible with time and, second, to study the molecular properties of toxicity. Respiration with and the uptake of succinate and ADP were measured in rabbit renal cortical mitochondria exposed for 2 to 6 h to 300 to 3,000 micrograms of cephalexin (nontoxic) or cephaloglycin or imipenem (nephrotoxic) per mL and then washed to remove the antibiotic. In vitro cephalexin reduced respiration only slightly and was therefore not studied further. Cephaloglycin and imipenem irreversibly reduced both respiration and succinate uptake. ADP uptake was unaffected by cephaloglycin and was slightly reduced by imipenem. Finally, cilastatin, which prevents the tubular necrosis produced by imipenem in vivo, reduced its mitochondrial toxicity in vitro. It is concluded that the pattern of in vitro injury of the nephrotoxic beta-lactams to mitochondrial substrate uptake and respiration evolves in a time-dependent and concentration-dependent manner, consistent with the proposed model of acylation and inactivation of substrate transporters, and that the protective action of cilastatin against imipenem occurs at least partly at a subcellular level.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2133431     DOI: 10.1681/ASN.V15815

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

1.  Analysis and physiological implications of renal 2-oxoglutaramate metabolism.

Authors:  I Nissim; S Wehrli; B States; I Nissim; M Yudkoff
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

2.  Treating critical illness: the importance of first doing no harm.

Authors:  Mervyn Singer; Paul Glynne
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

Review 3.  Antimicrobial-associated harm in critical care: a narrative review.

Authors:  Nishkantha Arulkumaran; Matthew Routledge; Sanmarié Schlebusch; Jeffrey Lipman; Andrew Conway Morris
Journal:  Intensive Care Med       Date:  2020-01-29       Impact factor: 17.440

4.  Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs).

Authors:  Xiaokui Huo; Qiang Meng; Changyuan Wang; Yanna Zhu; Zhihao Liu; Xiaodong Ma; Xiaochi Ma; Jinyong Peng; Huijun Sun; Kexin Liu
Journal:  Acta Pharm Sin B       Date:  2019-02-18       Impact factor: 11.413

5.  Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition.

Authors:  Stephany Jaiquel Baron; Martin S King; Edmund R S Kunji; Tom J J Schirris
Journal:  Theranostics       Date:  2021-03-05       Impact factor: 11.556

Review 6.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11

Review 7.  Antibiotics in critically ill children-a narrative review on different aspects of a rational approach.

Authors:  Nora Bruns; Christian Dohna-Schwake
Journal:  Pediatr Res       Date:  2021-12-06       Impact factor: 3.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.